Identification of Early Markers for ALS

Recruiting now · Not applicable

Conditions studied: Amyotrophic Lateral Sclerosis (ALS)

In brief

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies. In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.

Key facts

Study ID
NCT07213440
Run by
Institut National de la Santé Et de la Recherche Médicale, France
People needed
60
Starts
2024-09-30
Expected to finish
2027-04-01
Last updated by the study team
2026-07-07

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.